The transaction, valued at approximately $57 million, moves Pharsight into the Tripos portfolio. As a Tripos portfolio company, Pharsight will continue to develop and market integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.
Pharsight’s goal will continue to be one of helping customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Jim Hopkins, president and CEO of Tripos, said: “We’re excited to add Pharsight to the Tripos family. By acquiring Pharsight, we expect to provide our customers with important new products, key enabling technologies and scientific expertise, and to expedite the flow of information throughout discovery and development.”